ORY-1001 (RG-6016) - LSD1 Inhibitor. CAS# 1431326-61-2 430 Smiles: CC(C1CCN(CC1)S(=O)(=O)CC)N1C2=CC=CC=C2C(C(=O)NCC2=C(C=C(C)NC2=O)OC)=C1C

Smiles: CC(C1CCN(CC1)S(=O)(=O)CC)N1C2=CC=CC=C2C(C(=O)NCC2=C(C=C(C)NC2=O)OC)=C1C

The inhibition of mutant IDH2 and its neoactivity is therefore a potential therapeutic treatment for cancer

Solubility: H2O : 33

Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway

It is specific for class I and class II HDACs

ORY-1001 (RG-6016) - LSD1 Inhibitor. CAS# 1431326-61-2 430 Smiles: CC(C1CCN(CC1)S(=O)(=O)CC)N1C2=CC=CC=C2C(C(=O)NCC2=C(C=C(C)NC2=O)OC)=C1CORY 1001, CAS No. 1431326 61 2, is a highly potent and selective inhibitor of Lysine Specific Demethylase 1 (LSD1) with IC50 <20 nM. It is highly selective over related enzymes such as MAO A B. ORY 1001 affects AML stem cells, a sub population of cancer cells that has been proposed to be responsible for frequent relapses of the disease. It significantly reduces tumor cell load and increases survival time in mouse models of Acute Lymphoblastic